Allogene Therapeutics ALLO Business Segments — Facilities & IT-related spend

Similar metrics at other companies

BCAXReportable Segment — Facility costs, IT, office expense and other

$1.22M+8.9%

SNReportable Segment — Facilities and technology support costs

$20.9M-4.7%

GRALReportable Segment — Facilities

$5.25M-6.8%

SIONReportable Segment — Facility and information technology allocated expenses

$485K+10.2%

WEAVReportable Segment — Facilities costs

$2.43M+20.5%

PRMEReportable Segment — Facility related

$10.27M-6.4%

Questions, answered.

What is Allogene Therapeutics's business segments — facilities & it-related spend?

Allogene Therapeutics (ALLO) reported business segments — facilities & it-related spend of $6.42M in Q1 2026.

How has Allogene Therapeutics's business segments — facilities & it-related spend changed year-over-year?

Allogene Therapeutics's business segments — facilities & it-related spend decreased by 12.3% year-over-year, from $7.32M to $6.42M.

What is the long-term trend for Allogene Therapeutics's business segments — facilities & it-related spend?

Over 2 years (2023 to 2025), Allogene Therapeutics's business segments — facilities & it-related spend has grown at a -8.2% compound annual growth rate (CAGR), from $33.67M to $28.41M.

What does business segments — facilities & it-related spend mean?

This metric tracks the overhead costs associated with physical infrastructure, laboratory space, and information technology systems required to support business operations. It represents the fixed cost base necessary to maintain the company's research and administrative environment. Managing these expenses is critical for maintaining operational efficiency in a capital-intensive biotech model.